Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Dec 30;17(12):e0279591.
doi: 10.1371/journal.pone.0279591. eCollection 2022.

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Zixiang Wang  1 , Yinxuan Pei  1 , Weiwei Li  1 , Jingxiao Zhang  2 , Jinlong Liu  1
Affiliations
Meta-Analysis

Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

Zixiang Wang et al. PLoS One. .

Abstract

Background: To evaluate the clinical value of Aldo-keto reductase family 1 member B10 (AKR1B10) in the diagnosis and prognosis of hepatocellular carcinoma (HCC).

Methods: A search of the PubMed, China Biology Medicine, Cochrane, and Embase databases was performed to conduct meta-analyses to evaluate the accuracy of AKR1B10 in diagnosing HCC and to assess the impact on prognosis of patients after curative resection of HCC.

Results: A total of 12 different cohorts from 11 studies including 2747 HCC patients and 2053 controls showed that the pooled specificity and the pooled sensitivity of AKR1B10 for the diagnosis of HCC were 0.78 (95% CI: 0.69-0.85) and 0.85 (95% CI: 0.77-0.90), respectively. The pooled sensitivity and specificity of serum AKR1B10 for the diagnosis of HCC were 0.80 (95% CI: 0.70-0.86) and 0.87 (95% CI: 0.77-0.93), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of HCC were 0.78 (95% CI: 0.61-0.89) and 0.82 (95% CI: 0.69-0.90), respectively. The pooled sensitivity and specificity of AKR1B10 to distinguish HCC from benign liver disease were 0.71 (95% CI: 0.62-0.78) and 0.84 (95% CI: 0.77-0.89), respectively. The sensitivity and specificity of AKR1B10 combined with alpha fetoprotein (AFP) in the diagnosis of HCC were 0.84 (95% CI: 0.79-0.88) and 0.88 (95% CI: 0.73-0.95), respectively. The pooled sensitivity and specificity of AKR1B10 in malignant tumor tissue for the diagnosis of early-stage HCC were 0.85 (95% CI: 0.62-0.95) and 0.88 (95% CI: 0.81-0.93), respectively. A meta-analysis of five studies including 798 patients demonstrated that high AKR1B10 expression in liver malignant tumor was associated with better overall survival in patients with HCC after hepatectomy (HR = 0.54, 95% CI: 0.41-0.72, p < 0.001).

Conclusions: AKR1B10 exhibits a great clinical value in the diagnosis of HCC, especially for early-stage HCC, with excellent diagnostic accuracy. Furthermore, AKR1B10 expression can predict the prognosis of HCC patients after hepatic resection.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The flow diagram of study selection.
Fig 2
Fig 2. Overall methodology quality assessment of the included studies using the QUADAS criteria.
Fig 3
Fig 3. Forest plots of sensitivity (A), specificity (B), area under the curve (AUC) (C), and funnel plot (D) of AKR1B10 for diagnosing HCC among 11 studies.
Fig 4
Fig 4. Pooled sensitivity and specificity of AKR1B10 levels measured by different detection methods for the diagnosis of HCC.
Fig 5
Fig 5. Forest plot of the HR for the association between high AKR1B10 expression and overall survival in patients after hepatectomy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yang S, Liu L, Luo Y, Chen M, Li N, Xu L, et al.. (2018). Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients. Diabetes Res Clin Pract 143:239–44. doi: 10.1016/j.diabres.2018.07.018 - DOI - PubMed
    1. Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, Li ZN. (2018). Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett 16:1593–601. doi: 10.3892/ol.2018.8825 - DOI - PMC - PubMed
    1. Uthamalingam P, Das A, Behra A, Kalra N, Chawla Y. (2018). Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers. J Clin Exp Hepatol 8:173–80. doi: 10.1016/j.jceh.2017.09.005 - DOI - PMC - PubMed
    1. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62:10–29. doi: 10.3322/caac.20138 - DOI - PubMed
    1. Schwartz M, Roayaie S, Konstadoulakis M. (2007). Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4:424–32. doi: 10.1038/ncponc0844 - DOI - PubMed

MeSH terms